(data stored in ACNUC8465 zone)

SWISSPROT: MP2K4_HUMAN

ID   MP2K4_HUMAN             Reviewed;         399 AA.
AC   P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   11-DEC-2019, entry version 199.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4;
DE            Short=MAP kinase kinase 4;
DE            Short=MAPKK 4;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 1;
DE   AltName: Full=MAPK/ERK kinase 4;
DE            Short=MEK 4;
DE   AltName: Full=SAPK/ERK kinase 1;
DE            Short=SEK1;
DE   AltName: Full=Stress-activated protein kinase kinase 1;
DE            Short=SAPK kinase 1;
DE            Short=SAPKK-1;
DE            Short=SAPKK1;
DE   AltName: Full=c-Jun N-terminal kinase kinase 1;
DE            Short=JNKK;
GN   Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J.,
RA   Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by MEK
RT   and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=7716521; DOI=10.1126/science.7716521;
RA   Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C.,
RA   Mercurio F., Johnson G.L., Karin M.;
RT   "Identification of a dual specificity kinase that activates the Jun kinases
RT   and p38-Mpk2.";
RL   Science 268:286-290(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9622070;
RA   Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H.,
RA   Kern S.E.;
RT   "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as
RT   a genetically targeted tumor suppressor gene.";
RL   Cancer Res. 58:2339-2342(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH
RP   MAP3K11/MLK3.
RX   PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [12]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family members
RT   to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [13]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T.,
RA   Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of
RT   JNK3.";
RL   Science 290:1574-1577(2000).
RN   [14]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.m202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK
RT   signaling pathway. A new mode of regulation of the MAP kinase cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [15]
RP   DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11
RP   AND MAPK14.
RX   PubMed=12788955; DOI=10.1074/jbc.m304229200;
RA   Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.;
RT   "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and
RT   competes with similar docking sites in JNK substrates.";
RL   J. Biol. Chem. 278:32662-32672(2003).
RN   [16]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP kinase
RT   kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035;
RA   Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C.,
RA   Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.;
RT   "A scanning peptide array approach uncovers association sites within the
RT   JNK/beta arrestin signalling complex.";
RL   FEBS Lett. 583:3310-3316(2009).
RN   [20]
RP   REVIEW ON ACTIVITY REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional characteristics
RT   of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399.
RX   PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071;
RA   Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.;
RT   "Crystal structures of MKK4 kinase domain reveal that substrate peptide
RT   binds to an allosteric site and induces an auto-inhibition state.";
RL   Biochem. Biophys. Res. Commun. 400:369-373(2010).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND
RP   THR-279.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Essential
CC       component of the stress-activated protein kinase/c-Jun N-terminal
CC       kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the
CC       only known kinase to directly activate the stress-activated protein
CC       kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.
CC       MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation,
CC       but they differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the
CC       Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of
CC       the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK
CC       activation at least in response to proinflammatory cytokines, while
CC       other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which
CC       synergistically phosphorylate JNKs. MAP2K4 is required for maintaining
CC       peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also
CC       involved in mitochondrial death signaling pathway, including the
CC       release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7
CC       exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38
CC       MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- ACTIVITY REGULATION: Activated in response to a variety of cellular
CC       stresses, including UV and gamma-irradiation, heat shock,
CC       hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory
CC       cytokines. Also activated by developmental cues. MAP2K4/MKK4 is
CC       activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1,
CC       MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.
CC       {ECO:0000269|PubMed:9003778}.
CC   -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D
CC       domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11
CC       and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like
CC       MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and
CC       MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355,
CC       ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955,
CC       ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}.
CC   -!- INTERACTION:
CC       Q13233:MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P45985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P45985-2; Sequence=VSP_038838;
CC   -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle.
CC       It is also widely expressed in other tissues.
CC   -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking
CC       site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD
CC       sites bind to their specific upstream MAP kinase kinase kinases
CC       (MAP3Ks) and are essential for activation.
CC   -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site
CC       and is required for the binding to MAPK substrates.
CC   -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase
CC       kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/map2k4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html";
DR   EMBL; L36870; AAC41719.1; -; mRNA.
DR   EMBL; U17743; AAC50127.1; -; mRNA.
DR   EMBL; AF070090; AAC24130.1; -; Genomic_DNA.
DR   EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; CR536564; CAG38801.1; -; mRNA.
DR   EMBL; BT019676; AAV38482.1; -; mRNA.
DR   EMBL; AK131544; BAG54774.1; -; mRNA.
DR   EMBL; AK313053; BAG35884.1; -; mRNA.
DR   EMBL; DQ015703; AAY22176.1; -; Genomic_DNA.
DR   EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW89975.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89974.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89976.1; -; Genomic_DNA.
DR   EMBL; BC036032; AAH36032.1; -; mRNA.
DR   EMBL; BC060764; AAH60764.1; -; mRNA.
DR   CCDS; CCDS11162.1; -. [P45985-1]
DR   CCDS; CCDS62095.1; -. [P45985-2]
DR   PIR; I38901; I38901.
DR   RefSeq; NP_001268364.1; NM_001281435.1. [P45985-2]
DR   RefSeq; NP_003001.1; NM_003010.3. [P45985-1]
DR   PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399.
DR   PDB; 3ALO; X-ray; 2.60 A; A=80-399.
DR   PDB; 3VUT; X-ray; 3.50 A; A/B=80-399.
DR   PDBsum; 3ALN; -.
DR   PDBsum; 3ALO; -.
DR   PDBsum; 3VUT; -.
DR   SMR; P45985; -.
DR   BioGrid; 112315; 43.
DR   CORUM; P45985; -.
DR   IntAct; P45985; 18.
DR   MINT; P45985; -.
DR   STRING; 9606.ENSP00000410402; -.
DR   BindingDB; P45985; -.
DR   ChEMBL; CHEMBL2897; -.
DR   DrugCentral; P45985; -.
DR   GuidetoPHARMACOLOGY; 2065; -.
DR   iPTMnet; P45985; -.
DR   PhosphoSitePlus; P45985; -.
DR   BioMuta; MAP2K4; -.
DR   DMDM; 1170596; -.
DR   CPTAC; CPTAC-816; -.
DR   CPTAC; CPTAC-817; -.
DR   EPD; P45985; -.
DR   jPOST; P45985; -.
DR   MassIVE; P45985; -.
DR   MaxQB; P45985; -.
DR   PaxDb; P45985; -.
DR   PeptideAtlas; P45985; -.
DR   PRIDE; P45985; -.
DR   ProteomicsDB; 55703; -. [P45985-1]
DR   ProteomicsDB; 55704; -. [P45985-2]
DR   DNASU; 6416; -.
DR   Ensembl; ENST00000353533; ENSP00000262445; ENSG00000065559. [P45985-1]
DR   Ensembl; ENST00000415385; ENSP00000410402; ENSG00000065559. [P45985-2]
DR   GeneID; 6416; -.
DR   KEGG; hsa:6416; -.
DR   UCSC; uc002gnj.5; human. [P45985-1]
DR   CTD; 6416; -.
DR   DisGeNET; 6416; -.
DR   EuPathDB; HostDB:ENSG00000065559.14; -.
DR   GeneCards; MAP2K4; -.
DR   HGNC; HGNC:6844; MAP2K4.
DR   HPA; CAB007751; -.
DR   HPA; HPA060074; -.
DR   MIM; 601335; gene.
DR   neXtProt; NX_P45985; -.
DR   OpenTargets; ENSG00000065559; -.
DR   PharmGKB; PA30589; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00940000154744; -.
DR   InParanoid; P45985; -.
DR   KO; K04430; -.
DR   OMA; MKSNDCN; -.
DR   OrthoDB; 81952at2759; -.
DR   PhylomeDB; P45985; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SABIO-RK; P45985; -.
DR   SignaLink; P45985; -.
DR   SIGNOR; P45985; -.
DR   ChiTaRS; MAP2K4; human.
DR   EvolutionaryTrace; P45985; -.
DR   GeneWiki; MAP2K4; -.
DR   GenomeRNAi; 6416; -.
DR   Pharos; P45985; Tchem.
DR   PRO; PR:P45985; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P45985; protein.
DR   Bgee; ENSG00000065559; Expressed in 227 organ(s), highest expression level in frontal cortex.
DR   ExpressionAtlas; P45985; baseline and differential.
DR   Genevisible; P45985; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008545; F:JUN kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IBA:GO_Central.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IBA:GO_Central.
DR   DisProt; DP01400; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
DR   PRODOM; P45985.
DR   SWISS-2DPAGE; P45985.
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Stress response; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   CHAIN           2..399
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 4"
FT                   /id="PRO_0000086381"
FT   DOMAIN          102..367
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         108..116
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          37..52
FT                   /note="D domain"
FT   REGION          364..387
FT                   /note="DVD domain"
FT   COMPBIAS        5..19
FT                   /note="Gly/Ser-rich"
FT   ACT_SITE        229
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         131
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            45..46
FT                   /note="Cleavage; by anthrax lethal factor"
FT   SITE            58..59
FT                   /note="Cleavage; by anthrax lethal factor"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         58
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         58
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         257
FT                   /note="Phosphoserine; by MAP3K"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         261
FT                   /note="Phosphothreonine; by MAP3K"
FT                   /evidence="ECO:0000269|PubMed:9003778"
FT   VAR_SEQ         39
FT                   /note="G -> GFQINFCEKAQS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038838"
FT   VARIANT         16
FT                   /note="S -> R (in dbSNP:rs17855590)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_062963"
FT   VARIANT         142
FT                   /note="Q -> L (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040818"
FT   VARIANT         154
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040819"
FT   VARIANT         234
FT                   /note="N -> I (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040820"
FT   VARIANT         251
FT                   /note="S -> N (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040821"
FT   VARIANT         279
FT                   /note="A -> T (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs753665559)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040822"
FT   CONFLICT        118
FT                   /note="K -> R (in Ref. 4; CAG38801)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="E -> G (in Ref. 6; BAG35884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="P -> L (in Ref. 10; AAH60764)"
FT                   /evidence="ECO:0000305"
FT   STRAND          81..83
FT                   /evidence="ECO:0000244|PDB:3VUT"
FT   STRAND          85..88
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          93..95
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          101..103
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          107..110
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          112..121
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   TURN            122..124
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          127..134
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           139..153
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          164..169
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          171..178
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          182..184
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           185..194
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           202..223
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           232..234
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          235..237
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          243..245
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          249..251
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          255..259
FT                   /evidence="ECO:0000244|PDB:3VUT"
FT   STRAND          267..270
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           272..274
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           287..302
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   STRAND          312..314
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   STRAND          316..321
FT                   /evidence="ECO:0000244|PDB:3ALO"
FT   HELIX           338..347
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           352..354
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           358..361
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           365..372
FT                   /evidence="ECO:0000244|PDB:3ALN"
FT   HELIX           377..387
FT                   /evidence="ECO:0000244|PDB:3ALN"
SQ   SEQUENCE   399 AA;  44288 MW;  A472537F2F26770B CRC64;
     MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT
     LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV
     HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL
     MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS
     GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL
     ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE
     LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD
//

If you have problems or comments...

PBIL Back to PBIL home page